Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Annals of Hematology
Published in: Annals of Hematology 2/2016

01-01-2016 | Letter to the Editor

Cryptococcal meningoencephalitis associated with the long-term use of ruxolitinib

Authors: Chih-Cheng Chen, Yi-Yang Chen, Cih-En Huang

Published in: Annals of Hematology | Issue 2/2016

Login to get access

Excerpt

Dear Editor, …
Literature
1.
Harrison C, Kiladjian JJ, Al-Ali HK et al (2012) JAK inhibition with ruxolitinib versus best available therapy for myelofibrosis. N Engl J Med 366:787–798PubMedCrossRef
2.
Verstovsek S, Mesa RA, Gotlib J et al (2012) A double-blind, placebo-controlled trial of ruxolitinib for myelofibrosis. N Engl J Med 366:799–807PubMedCrossRef
3.
Heine A, Brossart P, Wolf D (2013) Ruxolitinib is a potent immunosuppressive compound: is it time for anti-infective prophylaxis? Blood 122:3843–3844PubMedCrossRef
4.
Shen CH, Hwang CE, Chen YY, Chen CC (2014) Hepatitis B virus reactivation associated with ruxolitinib. Ann Hematol 93:1075–1076PubMedCrossRef
5.
Wathes R, Moule S, Milojkovic D (2013) Progressive multifocal leukoencephalopathy associated with ruxolitinib. N Engl J Med 369:197–198PubMedCrossRef
6.
Goldberg RA, Reichel E, Oshry LJ (2013) Bilateral toxoplasmosis retinitis associated with ruxolitinib. N Engl J Med 369:681–683PubMedCrossRef
7.
Wysham NG, Sullivan DR, Allada G (2013) An opportunistic infection associated with ruxolitinib, a novel janus kinase 1,2 inhibitor. Chest 143:1478–1479PubMedCrossRef
8.
O'Shea JJ, Holland SM, Staudt LM (2013) JAKs and STATs in immunity, immunodeficiency, and cancer. N Engl J Med 368:161–170PubMedCrossRef
9.
Heine A, Held SA, Daecke SN et al (2013) The JAK-inhibitor ruxolitinib impairs dendritic cell function in vitro and in vivo. Blood 122:1192–1202PubMedCrossRef
10.
Schonberg K, Rudolph J, Vonnahme M et al (2015) JAK inhibition impairs NK cell function in myeloproliferative neoplasms. Cancer Res 75:2187–2199PubMedCrossRef
Metadata
Title
Cryptococcal meningoencephalitis associated with the long-term use of ruxolitinib
Authors
Chih-Cheng Chen
Yi-Yang Chen
Cih-En Huang
Publication date
01-01-2016
Publisher
Springer Berlin Heidelberg
Published in
Annals of Hematology / Issue 2/2016
Print ISSN: 0939-5555
Electronic ISSN: 1432-0584
DOI
https://doi.org/10.1007/s00277-015-2532-7

Other articles of this Issue 2/2016

Annals of Hematology 2/2016 Go to the issue

Letter to the Editor

Expansion of a BCR-ABL clone in a JAK2 V617F myeloproliferative neoplasm treated by ruxolitinib

Original Article

The Wilms Tumor-1 (WT1) rs2234593 variant is a prognostic factor in normal karyotype acute myeloid leukemia

Original Article

Non-Hodgkin lymphoma in the Far East: review of 730 cases from the international non-Hodgkin lymphoma classification project

Original Article

Phase 3 trial of three thalidomide-containing regimens in patients with newly diagnosed multiple myeloma not transplant-eligible

Letter to the Editor

Lymphomatoid granulomatosis mimicking vasculitis

Original Article

Outcomes of allogeneic hematopoietic cell transplantation in patients with biphenotypic acute leukemia
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Pediatric Cardiology Video

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

Cardiopulmonary Comorbidity Video

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Valvular Heart Disease Video

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

Watch now

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits